Enoxaparin sodium
- Generic Name
- Enoxaparin sodium
- Brand Names
- Lovenox, Inhixa
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- E47C0NF7LV
- Background
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hosp...
- Indication
Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.
...
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina
- Associated Therapies
- Percutaneous Coronary Intervention (PCI)
Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery
- Conditions
- First Posted Date
- 2006-03-23
- Last Posted Date
- 2007-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1225
- Registration Number
- NCT00306254
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
ABRIDGE: Low Molecular Weight Heparin in Bridging Patients After Mechanical Valve Replacement
- Conditions
- First Posted Date
- 2006-03-02
- Last Posted Date
- 2007-11-09
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 100
- Registration Number
- NCT00298285
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)
- Conditions
- First Posted Date
- 2006-02-09
- Last Posted Date
- 2007-01-31
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 200
- Registration Number
- NCT00289042
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
Enoxaparin in Acute Venous Thromboembolic Disease
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2010-02-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 251
- Registration Number
- NCT00265993
- Locations
- 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey
Patients Preference With Self-Injection: The PRISM Study
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2009-03-10
- Lead Sponsor
- Hamilton Health Sciences Corporation
- Target Recruit Count
- 100
- Registration Number
- NCT00253396
- Locations
- 🇨🇦
St. Joseph's Healthcare, Hamilton, Ontario, Canada
Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2009-06-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 47
- Registration Number
- NCT00191724
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Germany
Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3494
- Registration Number
- NCT00168818
- Locations
- 🇦🇺
1160.48.06102 Monash Medical Centre, Clayton, Victoria, Australia
🇦🇺1160.48.06104 Ecru, Box Hill, Victoria, Australia
🇦🇺1160.48.06110 Suite 13 level 4, Lismore, New South Wales, Australia
RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2101
- Registration Number
- NCT00168805
- Locations
- 🇦🇺
1160.25.06103 Boehringer Ingelheim Investigational Site, Ringwood East, Victoria, Australia
🇦🇹1160.25.04303 Boehringer Ingelheim Investigational Site, Wels, Austria
🇨🇿1160.25.42010 Boehringer Ingelheim Investigational Site, Chomutov, Czech Republic
The Use of Low Molecular Weight Heparin in Traumatic Brain Injury
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- Hennepin Healthcare Research Institute
- Target Recruit Count
- 300
- Registration Number
- NCT00170378
- Locations
- 🇺🇸
Hennepin County Medical Center, Minneapolis, Minnesota, United States
Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-05-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2615
- Registration Number
- NCT00152971
- Locations
- 🇲🇽
1160.24.05009 Traumatologia, Planta Baja, Guadalajara, Jalisco, Mexico
🇺🇸1160.24.01010 MIMA Century Research Associates, Melbourne, Florida, United States
🇺🇸1160.24.01033 Bone and Joint Clinic of Houston, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.